Landing
British Society for Haematology (BSH) 2022
Analysis of Anemia Persistence and Related Adverse Events in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
Breakthrough Hemolysis Rates Among Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switched From Eculizumab To Ravulizumab Treatment: A Real-World Analysis
Pegcetacoplan Patient Compliance Rates in PEGASUS and PRINCE Phase 3 Trials Compared to Published Oral Medication Compliance Rates in Literature
Pegcetacoplan Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria and Baseline Hemoglobin Levels at or above 10 Grams Per Deciliter
Quality of Life and Symptom Burden of Paroxysmal Nocturnal Haemoglobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe
The Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Pegcetacoplan Administration in Healthy Subjects
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.